Opportunity
Federal Register #DEA-1783
DEA controlled-substance importer and bulk-manufacturer registration applications
Buyer
Drug Enforcement Administration
Posted
October 19, 2026
Respond By
December 18, 2026
Identifier
DEA-1783
The DEA notice concerns applications to import or bulk-manufacture controlled substances for research and product development, rather than a purchase solicitation. - Government buyer / issuing agency: U.S. Department of Justice, Drug Enforcement Administration (DEA); no specific office is identified. - Named organizations: University of Mississippi’s National Center for Natural Products Research (NCNPR), Groff Health Inc., Halo Pharmaceutical Inc., and Organic Standards Solutions International, LLC. The excerpt does not identify Organic Standards Solutions International’s substances or application details. - Applicant activities and substances: - Groff Health Inc. seeks importer registration for ibogaine (7260), 3,4-methylenedioxymethamphetamine (7405), psilocybin (7437), and psilocyn (7438), for internal research, clinical trials, analytical purposes, and customer distribution. - University of Mississippi’s NCNPR seeks bulk-manufacturer registration for marihuana (7360), marihuana extract (7350), and tetrahydrocannabinols (7370), for product development and reference standards. The extract and tetrahydrocannabinols would be derived from marihuana. - Halo Pharmaceutical Inc. seeks importer registration for psilocybin (7437), for formulation development and clinical trials. - The listed substances are Schedule I controlled substances. No purchase quantities, products or services for sale, or performance period are specified.
Description
The National Center for Natural Products Research University of Mississippi/NCNPR applied to register as a bulk manufacturer of controlled substances. The application covers marihuana extract, marihuana, and tetrahydrocannabinols. The organization plans to manufacture the substances for product development and reference standards; marihuana extract and tetrahydrocannabinols are to be extracted from marihuana. Comments, objections, or hearing requests may be submitted on or before December 18, 2026.